New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks ...

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Lilly, Johnson & Johnson, Novartis and AstraZeneca have now announced manufacturing investments in the U.S., trying to ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

As trade tensions between the US and China escalate, a small-cap ASX biotech could become a strategic gateway for bringing ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9. Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in ...

Several states are reporting cases of measles, a highly contagious viral disease. Both children and adults can get measles.